ChromaDex Shares Promising Findings from Clinical Study Showcasing ​​the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction

This is the first study to investigate the safety and tolerability of NR in a randomized, placebo-controlled trial of patients with heart failure, marking a milestone for future clinical research

Related Keywords

University Of Washington ,Washington ,United States ,Seattle ,Andrew Shao ,Kevin Obrien ,Global Scientific Regulatory Affairs ,Division Of Cardiology ,Department Of Anesthesiology ,Chromadex External Research Program ,Chromadex Corp ,Journal Of The American College Cardiology ,University Of Washington School Medicine ,Metabolism Center ,Department Of Medicine ,American College ,Translational Science ,Kevino Brien ,Rong Tian ,Pain Medicine ,Washington School ,Chromadex Senior Vice President ,Global Scientific ,